<h1>Administration proposes up to 200% tariffs on imported pharmaceuticals under Section 232, risking shortages and higher prices</h1> The administration proposes steep tariffs on imported pharmaceuticals-potentially up to 200%-and is using investigations under Section 232 of the Trade Expansion Act (national security grounds) to justify measures. Announced delays of a year to 18 months aim to allow stockpiling and reshoring, but tariffs could extend to active pharmaceutical ingredients, raising legal and commercial risks for generic suppliers and complicating supply chains. Economically vulnerable manufacturers may exit the U.S. market, raising shortages and price-inflation concerns. Legal issues include the scope of Section 232 authority, possible exemptions for low-margin generics, administrative rulemaking requirements, and likely challenges under domestic trade law and international obligations.